312 related articles for article (PubMed ID: 31216647)
21. Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis.
Wulf-Goldenberg A; Hoffmann J; Becker M; Brzezicha B; Walther W
Methods Mol Biol; 2021; 2294():43-58. PubMed ID: 33742393
[TBL] [Abstract][Full Text] [Related]
22. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
23. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF; Kondrashova O; Smith D; Nones K; Sengal AT; Ju R; Packer LM; Koufariotis LT; Kazakoff SH; Davidson AL; Ramarao-Milne P; Lakis V; Newell F; Rogers R; Davies C; Nicklin J; Garrett A; Chetty N; Perrin L; Pearson JV; Patch AM; Waddell N; Pollock PM
Genome Med; 2022 Jan; 14(1):3. PubMed ID: 35012638
[TBL] [Abstract][Full Text] [Related]
24. Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.
Moy RH; Walch HS; Mattar M; Chatila WK; Molena D; Strong VE; Tang LH; Maron SB; Coit DG; Jones DR; Hechtman JF; Solit DB; Schultz N; de Stanchina E; Janjigian YY
JCO Precis Oncol; 2022 Feb; 6():e2100242. PubMed ID: 35138918
[TBL] [Abstract][Full Text] [Related]
25. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
Guillen KP; Fujita M; Butterfield AJ; Scherer SD; Bailey MH; Chu Z; DeRose YS; Zhao L; Cortes-Sanchez E; Yang CH; Toner J; Wang G; Qiao Y; Huang X; Greenland JA; Vahrenkamp JM; Lum DH; Factor RE; Nelson EW; Matsen CB; Poretta JM; Rosenthal R; Beck AC; Buys SS; Vaklavas C; Ward JH; Jensen RL; Jones KB; Li Z; Oesterreich S; Dobrolecki LE; Pathi SS; Woo XY; Berrett KC; Wadsworth ME; Chuang JH; Lewis MT; Marth GT; Gertz J; Varley KE; Welm BE; Welm AL
Nat Cancer; 2022 Feb; 3(2):232-250. PubMed ID: 35221336
[TBL] [Abstract][Full Text] [Related]
26. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived xenografts as in vivo models for research in urological malignancies.
Inoue T; Terada N; Kobayashi T; Ogawa O
Nat Rev Urol; 2017 May; 14(5):267-283. PubMed ID: 28248952
[TBL] [Abstract][Full Text] [Related]
28. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
29. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
31. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
Cho SY; Chae J; Na D; Kang W; Lee A; Min S; Kang J; Choi B; Lee J; Sung CO; Chuang JH; Lee C; Lee WS; Park H; Kim JI
Clin Cancer Res; 2019 May; 25(9):2821-2834. PubMed ID: 30670495
[TBL] [Abstract][Full Text] [Related]
32. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
33. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
Allaway RJ; Fischer DA; de Abreu FB; Gardner TB; Gordon SR; Barth RJ; Colacchio TA; Wood M; Kacsoh BZ; Bouley SJ; Cui J; Hamilton J; Choi JA; Lange JT; Peterson JD; Padmanabhan V; Tomlinson CR; Tsongalis GJ; Suriawinata AA; Greene CS; Sanchez Y; Smith KD
Oncotarget; 2016 Mar; 7(13):17087-102. PubMed ID: 26934555
[TBL] [Abstract][Full Text] [Related]
34. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.
Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C
BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434
[TBL] [Abstract][Full Text] [Related]
35. Modeling rectal cancer to advance neoadjuvant precision therapy.
Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
[TBL] [Abstract][Full Text] [Related]
36. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
37. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.
Georgopoulou D; Callari M; Rueda OM; Shea A; Martin A; Giovannetti A; Qosaj F; Dariush A; Chin SF; Carnevalli LS; Provenzano E; Greenwood W; Lerda G; Esmaeilishirazifard E; O'Reilly M; Serra V; Bressan D; ; Mills GB; Ali HR; Cosulich SS; Hannon GJ; Bruna A; Caldas C
Nat Commun; 2021 Mar; 12(1):1998. PubMed ID: 33790302
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
39. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
[TBL] [Abstract][Full Text] [Related]
40. Prioritizing therapeutic targets using patient-derived xenograft models.
Lodhia KA; Hadley AM; Haluska P; Scott CL
Biochim Biophys Acta; 2015 Apr; 1855(2):223-34. PubMed ID: 25783201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]